Year Published
- 2008 (3) Apply 2008 filter
- 2009 (10) Apply 2009 filter
- 2010 (10) Apply 2010 filter
- 2011 (7) Apply 2011 filter
- (-) Remove 2012 filter 2012
- 2013 (2) Apply 2013 filter
- 2014 (1) Apply 2014 filter
- 2015 (5) Apply 2015 filter
- 2016 (11) Apply 2016 filter
- 2017 (8) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (2) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- Global (1) Apply Global filter
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (0)
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (1) Apply Farmer First filter
- LSMS & LSMS-ISA (2) Apply LSMS & LSMS-ISA filter
- Other Datasets (0)
Current search
- (-) Remove Technology filter Technology
- (-) Remove Food Security & Nutrition filter Food Security & Nutrition
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove 2012 filter 2012
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This brief explores how two datasets – The Tanzania National Panel Survey (TZNPS) and the TNS-Research International Farmer Focus (FF) – predict the determinants of inorganic fertilizer use among smallholder farmers in Tanzania by using regression analysis. The (TZNPS) was implemented by the Tanzania National Bureau of Statistics, with support from the World Bank Living Standards Measurement Study – Integrated Surveys on Agriculture (LSMS-ISA) team and includes extensive information on crop productivity and input use. The FF survey was funded by the Bill and Melinda Gates Foundation and implemented by TNS Research International and focuses on the on the behaviors and attitudes of smallholder farmers in Tanzania. The two datasets produce relatively comparable results for the primary predictors of inorganic fertilizer use: agricultural extension and whether or not a household grows cash crops. However, other factors influencing input use produce results that vary in magnitude and direction of the effect across the two datasets. Distinct survey instrument designs make it difficult to test the robustness of the models on input use other than inorganic fertilizer. This brief uses data inorganic fertilizer use, rather than adoption per se. The TZNPS did not ask households how recently they began using a certain product and although the FF survey asked respondents how many new inputs were tried in the past four planting seasons, they did not ask specifically about inorganic fertilizer.
This report investigates the potential environmental and socio-economic benefits and costs of glyphosate resistant cassava. Glyphosate resistant crops (also referred to as glyphosate tolerant) have been rapidly adopted by a number of crop producers because they simplify and/or reduce the cost of weed management. Glyphosate resistant crops also provide external environmental benefits by promoting reduced tillage agriculture, decreasing erosion and increasing soil health. However, glyphosate resistant crops also have some environmental costs, potentially leading to increased use of herbicides and environmental contamination. Because transgenic glyphosate resistant cassava is not currently in use, literature on its potential environmental and socioeconomic costs and benefits is limited. Therefore, this report draws on the literature for glyphosate resistant crops that are in current use, including maize, soybeans, sugar beets and canola (rapeseed). We find that socioeconomic and environmental impacts of glyphosate resistant crops differ by crop-type, agroecological conditions, production systems and local regulatory structure. Therefore, some benefits and costs associated with other glyphosate resistant crops may not be applicable to glyphosate resistant cassava.
This brief provides an overview of the national and zonal characteristics of agricultural production in Tanzania using the 2008/2009 wave of the Tanzania National Panel Survey (TZNPS), part of the Living Standards Measurement Study – Integrated Surveys on Agriculture (LSMS-ISA). More detailed information and analysis is available in the separate EPAR Tanzania LSMS-ISA Reference Report, Sections A-G.